NCT00464919View on ClinicalTrials.gov

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

March 31, 2009

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

DRUG

tegafur/uracil (UFUR®)

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT00464919 - Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter